Andree Blaukat

Biopharma, Global R&D, Merck Healthcare, Frankfurter Str. 250
Darmstadt, HE 64293, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer.

M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer.

Journal: Molecular cancer therapeutics

Published: August 15, 2024

Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models.

Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models.

Journal: Molecular cancer therapeutics

Published: February 15, 2023

Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death.

Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death.

Journal: Aging

Published: December 15, 2022

Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.

Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.

Journal: Molecular cancer therapeutics

Published: October 18, 2022

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.

Journal: Molecular cancer therapeutics

Published: September 09, 2022

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.

Journal: Molecular cancer therapeutics

Published: November 25, 2021

DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.

DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.

Journal: Molecular cancer research : MCR

Published: July 29, 2021

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations.

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations.

Journal: iScience

Published: October 02, 2020

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.

Journal: Scientific reports

Published: April 18, 2020

Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics.

Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics.

Journal: Molecular oncology

Published: October 17, 2019

Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies.

Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies.

Journal: Drug discovery today

Published: September 29, 2019

DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia.

DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia.

Journal: Frontiers in oncology

Published: September 09, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026